***Background.*** To the best of our knowledge, there are limited reports of enteric fever cases in returning travelers. Following the revision of levofloxacin and ciprofloxacin breakpoints by the Clinical Laboratory Standard Institute (CLSI) in 2012, we determined clinical characteristics, antibiotics susceptibility, and relapse risk factors for enteric fever in Japan.

***Methods.*** The retrospective cross-sectional study was conducted in a single institute in Tokyo, Japan between January 2006 and December 2013. Enteric fever was defined as isolation of *Salmonella* Typhi or *S*. Paratyphi from blood and/or stool in a patient with fever.

###### 

Relationship between isolate source and fluoroquinolone sensitivity (n=29)

                 Isolate source   
  -------------- ---------------- --------
  Susceptible    0 (0)            4 (80)
  Intermediate   18 (75)          1 (20)
  Resistant      6 (25)           0 (0)

***Results.*** Of the 35 cases of enteric fever that were diagnosed during the study period, 28 (80%) patients had returned from South Asia and 6 (17%), from Southeast Asia. Only 8 (23%) patients had a pre-travel consultation, including 4 (11%) with a typhoid vaccination in previous 2 years. Only 16 (47%) of 34 fulfilled the criteria for sepsis, while 19 (90%) of 21 cases experienced relative bradycardia. Of 35 cases, rose spots were observed in only 2 (6%) cases and eosinopenia (0-1%) was present in 34 (97%). Of 32 cases with image findings observations include splenomegaly (n = 17, 52%), paraileocecal lymph node swelling (n = 8, 24%), and ileoceccal thickening (n = 4, 11%). All cases were sensitive to ceftriaxione except for 1 case of ESBL producing *Enterobacteriaceae*. None of the detected bacteria from South Asia were susceptible to fluoroquinolone according to the CLSI 2012 breakpoint (table). The relapse rate was 8.6% with no significant risk for relapse related to days from onset to treatment (*P* = 0.28) or sepsis (*P* = 0.71). However, \>7 days to reach defervescence was a significantly relapse risk factor (*P* = 0.035).

***Conclusion.*** Fluoroquinolones are not recommended as empiric treatment for enteric fever in travelers returning from South Asia. While there are no concerns for relapse based on the time to start treatment and the severity at the initial presentation, there are for prolonged duration (\>7 days) to reach defervescence.
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